Add Row
Add Element
Glytain Logo
update
Glytain.com
update
Add Element
  • Home
  • Categories
    • Healthcare
    • Innovation
    • Digital
    • Marketing
    • Analysis
    • Insights
    • Trends
    • Empowerment
    • Providers
    • Tech News
    • Extra News
March 01.2025
3 Minutes Read

Sam Neville Joins Highland Marketing Advisory Board: A Step Towards Digital Health Innovation

Highland Marketing logo with bold text and orange accent

Sam Neville: Championing Digital Transformation in Nursing

In an exciting development for the health tech industry, Sam Neville, a seasoned chief nursing information officer, is set to join the Highland Marketing advisory board. With over three decades of experience in nursing, Neville brings a wealth of expertise and a passionate commitment to improving healthcare through technology.

Currently serving as the associate director of clinical applications and CNIO at the Mid and South Essex NHS Trust, Neville has been instrumental in advancing the role of digital solutions in patient care. Her journey in nursing began at Basildon and Thurrock University Hospital, where she developed a keen interest in surgery. Over the years, she has held numerous leadership positions, culminating in her focus on clinical informatics, where she advocates for integrating IT systems that work effectively for healthcare providers.

Bridging Nursing Expertise and Digital Innovation

Sam strongly believes in the potential of digital health tools to enhance the quality of care. During her tenure, she successfully launched the e-NEWS scoring system, demonstrating how visibility into patient data can empower clinical teams to make informed decisions. “I am still a registered nurse, but I am using that to make sure IT works for nurses and midwives,” Sam stated, underscoring her unique approach to merging clinical practice with digital advancements.

This dual role positions Neville as an integral link between nursing professionals and tech developers, a perspective that is crucial as the NHS looks to future-proof its digital landscape. “We need to ensure that new technologies are user-friendly and equip our nursing workforce with the skills they need,” she adds, reflecting on the evolving expectations of modern nurses.

The Importance of Nursing Perspectives in Digital Health

Mark Venables, CEO of Highland Marketing, emphasizes the significance of incorporating nursing insights in discussions about digital health. With nurses constituting almost a third of the NHS workforce, their perspectives are invaluable when planning and implementing IT solutions. “Sam will bring that perspective to the advisory board’s discussions, providing vital insights for our clients in health and medtech,” said Venables.

Neville’s upcoming role signifies a proactive step towards a more integrated approach where nursing experiences shape the development of health technologies. Her involvement will help ensure that the digital tools being developed are not only effective but also aligned with the day-to-day realities faced by nursing professionals.

Preparing for the Future of Nursing and Digital Health

Though her work with the Phillips-Ives Review remains unpublished, Neville argues that the conclusions drawn should guide the digital components of the forthcoming 10 Year Health Plan. She points out that misconceptions about nurses' digital literacy persist, even as a new generation of tech-savvy nurses enters the field. “We have many nurses who are ready and willing to engage with technology in ways that enhance patient care,” she asserted. This shift is pivotal in ensuring that healthcare systems evolve in tandem with the capabilities of their workforce.

Through her membership on the advisory board, Neville aims to foster dialogue and collaboration amongst a diverse group of health tech experts, further highlighting the need for shared learning across disciplines. Her mission aligns with the larger aim of digital transformation in healthcare, where every stakeholder, especially nurses, plays a critical role.

Healthcare

Write A Comment

*
*
Related Posts All Posts

Former CDC Leaders Alarmed by Vaccine Guidance Meeting Amidst Political Turmoil

Update A Pivotal Moment for Public HealthThis week marked a significant juncture for the Centers for Disease Control and Prevention (CDC) as two former leaders testified before a Senate committee. Their dramatic depictions of the agency, characterized by turmoil and a perilous drift from scientific rigor, raise vital alarms regarding America’s public health framework.Concerns Over Vaccine GuidanceAmidst ongoing concerns about the CDC's direction, the agency's vaccine advisory panel convened, facing the critical task of discussing multiple childhood vaccines. Susan Monarez, the former director who was abruptly dismissed just weeks after taking the helm, expressed profound fears that weakened vaccine protections could lead to the resurgence of preventable diseases. Her insights serve as a clarion call amidst growing uncertainty over vaccine policies.Political Influences in Health PolicyRobert F. Kennedy Jr., current Secretary of Health and Human Services and long-time vaccine critic, has been scrutinized for his influence over the CDC's operations. Monarez revealed startling details during her testimony; she claimed Kennedy sought to impose directives aimed at stifling independent scientific inquiry. His request for blanket approval of recommendations without rigorous scientific backing raises questions about the integrity of vaccine guidance going forward.The Implications for Public TrustThe ongoing narrative highlights a crucial intersection where politics and public health collide. If experts within the CDC are disempowered and crucial scientific processes are undermined, it may result in public mistrust. With vaccine hesitancy already at alarming levels, the ability of the CDC to champion effective health policies is more critical than ever.

Navigating Cloud Lifecycle Management: What Healthcare Organizations Must Know

Update Understanding Cloud Lifecycle Management in HealthcareAs healthcare organizations increasingly adopt cloud technology, understanding cloud lifecycle management becomes crucial. Over the past five to seven years, healthcare systems have transitioned from traditional on-premises data centers to cloud infrastructure with relative success. This migration has instilled confidence in healthcare leaders, enabled by providers like Amazon Web Services (AWS) that offer compliant and secure solutions for sensitive health data.Tackling Cloud Management ChallengesDespite these advancements, challenges persist in cloud lifecycle management. Many healthcare organizations encounter difficulties in securing buy-in from various stakeholders, including executives and clinicians. The primary concern remains the security of protected health information (PHI), as the handling of sensitive data requires stringent compliance with regulations like HIPAA. Awareness of these factors can help organizations make informed decisions about cloud architecture tailored to their operational needs.The Importance of Infrastructure ComplianceIn today’s rapidly evolving landscape, healthcare IT teams must carefully evaluate cloud architecture, services needed, and lifecycle policies to ensure not only operational efficiency but also financial responsibility. Balancing these needs with compliance presents a formidable task that healthcare leaders must master as they navigate their cloud journeys. By focusing on strategic planning and management, organizations can address these challenges head-on, paving the way for successful cloud integration.Actionable Insights for Successful Cloud TransitionHealthcare organizations embarking on a cloud migration should prioritize comprehensive training for staff and ongoing evaluation of cloud services. Establishing clear policies around data security and compliance will not only bolster patient trust but also enhance operational efficiency. As these organizations forge ahead, embracing the cloud can unlock significant benefits, including improved patient care, streamlined operations, and enhanced data security.

Roche's $3.5 Billion Acquisition of 89bio: A Game Changer for Obesity Treatment

Update Roche Takes a Big Step in Tackling Obesity with 89bio AcquisitionIn a significant move to expand its obesity treatment offerings, Roche has announced its acquisition of 89bio, a biotech company focused on creating solutions for a liver condition known as MASH (metabolic dysfunction-associated steatotic liver disease). The deal is valued at up to $3.5 billion and underscores the pharmaceutical giant's commitment to addressing the growing epidemic of obesity and its related health complications.Roche is set to pay $14.50 per share for 89bio, which represents a substantial 80% premium compared to the biotech’s last closing price. This gives 89bio an equity value of $2.4 billion, with additional contingent rights potentially pushing the total to $3.5 billion. The centerpiece of this acquisition is 89bio’s candidate drug, pegozafermin, which has shown promise in treating MASH, a disease characterized by liver inflammation leading to fibrosis. As obesity rates soar globally, conditions like MASH are becoming increasingly prevalent, raising concerns among healthcare professionals.The Broader Impact of Roche's AcquisitionWith Roche's acquisition of 89bio, the pharmaceutical landscape is poised for significant changes. Obesity not only affects individual health but also imposes a heavy burden on healthcare systems worldwide. By investing in innovative treatments, Roche aims to lead in the competitive market focused on obesity and its complications, including cirrhosis and liver cancer, providing hope for millions suffering from these conditions.Future Trends in Biopharmaceutical InvestmentsThis deal reflects a broader trend within the pharmaceutical industry where major players are investing heavily in biotech companies that offer solutions for chronic conditions. As lifestyle diseases like obesity become more entrenched, the need for effective treatments will likely drive such investments. Roche's move signals to the market that addressing obesity could lead to rewarding opportunities for both patients and investors, creating a ripple effect across the healthcare industry.What This Means for YouThis acquisition not only marks a pivotal moment for Roche and 89bio but also highlights the importance of investing in healthcare solutions that address pressing health issues. For those interested in the intersection of biotechnology and health trends, observing how Roche's investment pans out could provide valuable insights into the future of obesity treatment.

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*